The DOI matches its Crossref record; 221 of the 221 references it cites were found in a registry or an index.
Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations
Open accessAbstract
Cancer and cardiovascular (CV) disease are the most prevalent diseases in the developed world. Evidence increasingly shows that these conditions are interlinked through common risk factors, coincident in an ageing population, and are connected biologically through some deleterious effects of anticancer treatment on CV health. Anticancer therapies can cause a wide spectrum of short- and long-term cardiotoxic effects. An explosion of novel cancer therapies has revolutionised this field and dramatically altered cancer prognosis. Nevertheless, these new therapies have introduced unexpected CV complications beyond heart failure. Common CV toxicities related to cancer therapy are defined, along with suggested strategies for prevention, detection and treatment. This ESMO consensus article proposes to define CV toxicities related to cancer or its therapies and provide guidance regarding prevention, screening, monitoring and treatment of CV toxicity. The majority of anticancer therapies are associated with some CV toxicity, ranging from asymptomatic and transient to more clinically significant and long-lasting cardiac events. It is critical however, that concerns about potential CV damage resulting from anticancer therapies should be weighed against the potential benefits of cancer therapy, including benefits in overall survival. CV disease in patients with cancer is complex and treatment needs to be individualised. The scope of cardio-oncology is wide and includes prevention, detection, monitoring and treatment of CV toxicity related to cancer therapy, and also ensuring the safe development of future novel cancer treatments that minimise the impact on CV health. It is anticipated that the management strategies discussed herein will be suitable for the majority of patients. Nonetheless, the clinical judgment of physicians remains extremely important; hence, when using these best clinical practices to inform treatment options and decisions, practitioners should also consider the individual circumstances of their patients on a case-by-case basis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition to the cumulative cisplatin dose, peak drug exposure, young age at treatment, co-administration of other ototoxic drugs and others are well-defined risk factors for more severe auditory damage 167,168,169 .”
From Osteosarcoma (2022) · cites this paper as [167]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O. D., et al. (2021) · PubMed · doi:10.1093/eurheartj/ehab670 · Cited by 20,604
Self-citation2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536
Self-citationSlamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw128 · Cited by 11,429
Self-citationStone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.006 · Cited by 6,616
Cancer treatment and survivorship statistics, 2016
Miller, K. D., Siegel, R. L., Lin, C. C., Mariotto, A. B., Kramer, J. L., Rowland, J. H., Stein, K. D., Alteri, R., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21349 · Cited by 6,066
2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.592 · Cited by 5,866
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.005 · Cited by 4,945
Cited by
Sorted by citations
Items 301–400 of 999
Roberto, M., Panebianco, M., Aschelter, A. M., Buccilli, D., Cantisani, C., Caponnetto, S., Cortesi, E., D’Amuri, S., Fofi, C., Ierinò, D., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1026978 · Cited by 12
Guarding the heart: How SGLT-2 inhibitors protect against chemotherapy-induced cardiotoxicity
Vafa, R. G., Sabahizadeh, A., & Mofarrah, R. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.102350 · Cited by 13
Dafaalla, M. D., Abramov, D., Spall, H. G. C. V., Ghosh, A. K., Gale, C. P., Zaman, S. J., Rashid, M. O., & Mamas, M. A. (2024) · JACC CardioOncology · doi:10.1016/j.jaccao.2023.10.011 · Cited by 13
Lisi, D. D., Madaudo, C., Faro, D. C., Rossetto, L., Triolo, O. F., Losi, V., Galassi, A. R., Monte, I. P., & Novo, G. (2024) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001589 · Cited by 13
Health Literacy, Individual and Community Engagement, and Cardiovascular Risks and Disparities
Taylor, L. L., Hong, A. S., Hahm, K. J., Kim, D., Smith-Morris, C. M., & Zaha, V. G. (2024) · JACC CardioOncology · doi:10.1016/j.jaccao.2024.03.010 · Cited by 13
Cardiac Safety of Reduced Cardiotoxicity Surveillance During HER2-Targeted Therapy
Yu, A. F., Dang, C. T., Moskowitz, C. S., Meza, A. M., DeFusco, P. A., Oligino, E. J., Chen, C. L., Sanford, R. A., Drullinsky, P. R., Bromberg, J., et al. (2025) · JACC CardioOncology · doi:10.1016/j.jaccao.2025.05.006 · Cited by 13
Platini, F., Cavalieri, S., Alfieri, S., Bergamini, C., Resteghini, C., Bottiglieri, A., Colombo, E. V., Mazzeo, L., Licitra, L. F., Paolini, B., et al. (2021) · Endocrine · doi:10.1007/s12020-021-02702-4 · Cited by 13
Goričar, K., Dugar, F., Dolžan, V., & Marinko, T. (2022) · Cancers · doi:10.3390/cancers14184365 · Cited by 15
Kim, L., Loccoh, E. C., Sanchez, R., Ruz, P., Anaba, U., Williams, T. M., Slivnick, J. A., Vallakati, A., Baliga, R. R., Ayan, A. S., et al. (2020) · Current Cardiology Reports · doi:10.1007/s11886-020-01380-4 · Cited by 13
He, X., Ji, J., Dai, X., Qdaisat, A. Z., Esteva, F. J., Hortobágyi, G. N., & Yeung, S. J. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4162 · Cited by 13
Abdel-Qadir, H. M., Tai, F., Croxford, R., Austin, P. C., Amir, E., Arguelles, O. C., Ross, H. J., Lee, D. S., & Thavendiranathan, P. (2021) · Circulation Heart Failure · doi:10.1161/circheartfailure.120.008110 · Cited by 13
Subramaniam, S., Kong, Y., Zaharah, H., Uiterwaal, C. S. P. M., Richard, A., Tab, N. A., Deniel, A., Chee, K., Bustamam, R. S., See, M., et al. (2021) · ecancermedicalscience · doi:10.3332/ecancer.2021.1293 · Cited by 13
Viamonte, S., Joaquim, A. V., Alves, A. J., Vilela, E., Capela, A., Ferreira, C., Duarte, B., Rato, N. D., Tavares, A. I., Santos, M., et al. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.09.075 · Cited by 13
The cardio-oncology multidisciplinary team: beyond the basics
Bennetts, J. D., Williams, T. D., Beavers, C. J., Moore, H., Robson, C., Warner, T., Dent, S. F., Sverdlov, A. L., & Ngo, D. T. M. (2025) · Cardio-Oncology · doi:10.1186/s40959-025-00369-8 · Cited by 14
Self-citationPharmacological prevention in cardio-oncology: from bench-to-bedside
Арманович, А. А., Вачиковна, П. Н., Fogacci, F., Urazova, O. I., Jndoyan, Z., Mirzoyan, L. R., Avetisyan, G., Bernardi, M., Spadafora, L., Shafie, D., et al. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10575-2 · Cited by 12
Gheorghe, G. S. (2021) · FARMACIA · doi:10.31925/farmacia.2021.6.5 · Cited by 12
Methods of screening, monitoring and management of cardiac toxicity induced by chemotherapeutics
Afrin, H., Salazar, C. J. J., Kazi, M., Ahamad, S. R., Alharbi, M., & Nurunnabi, M. (2022) · Chinese Chemical Letters · doi:10.1016/j.cclet.2022.01.011 · Cited by 12
Liu, J., Cao, Y., Zhu, K., Yao, S., Yuan, M., Kong, X., Liu, X., Li, Y., Cui, Y., Han, X., et al. (2022) · Quantitative Imaging in Medicine and Surgery · doi:10.21037/qims-22-41 · Cited by 12
Tales from the future—nuclear cardio-oncology, from prediction to diagnosis and monitoring
Mikaïl, N., Chequer, R. D. P., Impériale, A., Meisel, A., Bengs, S., Portmann, A., Gimelli, A., Buechel, R. R., Gebhard, C., & Rossi, A. (2023) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jead168 · Cited by 12
Circulating Biomarkers for Monitoring Chemotherapy-Induced Cardiotoxicity in Children
Meo, L., Savarese, M., Munno, C., Mirabelli, P., Ragno, P., Leone, O., & Alfieri, M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15122712 · Cited by 12
Respiratory Pathology and Cardiovascular Diseases: A Scoping Review
Campos‐Rodríguez, F., Chiner, E., de la Rosa, D., Cosío, B. G., Hernádez-Hernández, J. R., Jiménez, D., Méndez, R., Molina‐Molina, M., Campos, J. G. S., Vaquero, J. M., et al. (2024) · Open Respiratory Archives · doi:10.1016/j.opresp.2024.100392 · Cited by 17
Prevention of cancer-therapy related cardiac dysfunction
Haj‐Yehia, E., Michel, L., Mincu, R. I., Rassaf, T., & Totzeck, M. (2025) · Current Heart Failure Reports · doi:10.1007/s11897-025-00697-x · Cited by 16
Koo, C. Y., Tai, B., Chan, D. K. H., Tan, L. L., Tan, K., & Lee, C. (2021) · World Journal of Surgical Oncology · doi:10.1186/s12957-021-02125-5 · Cited by 12
Cardiovascular Complications Associated with Contemporary Lung Cancer Treatments
Sase, K., Fujisaka, Y., Shoji, M., & Mukai, M. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00869-6 · Cited by 13
Terpos, E., Stamatelopoulos, K. S., Makris, N., Georgiopoulos, G. A., Ntanasis‐Stathopoulos, I., Gavriatopoulou, M., Laina, A., Eleutherakis‐Papaiakovou, E., Fotiou, D., Kanellias, N., et al. (2021) · Cancers · doi:10.3390/cancers13205057 · Cited by 12
Shin, D. W., Jung, K., Ha, J., & Bae, J. (2022) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2022.33.e23 · Cited by 12
An integrated approach to cardioprotection in lymphomas
Maraldo, M. V., Levis, M., Andreis, A., Armenian, S. H., Bates, J. E., Brady, J. L., Ghigo, A., Lyon, A. R., Manisty, C., Ricardi, U., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00082-5 · Cited by 12
Self-citationInvolvement of kallikrein‐PAR2 ‐proinflammatory pathway in severe trastuzumab‐induced cardiotoxicity
Sasaki, R., Kurebayashi, N., Eguchi, H., Horimoto, Y., Shiga, T., Miyazaki, S., Kashiyama, T., Akamatsu, W., & Saito, M. (2022) · Cancer Science · doi:10.1111/cas.15508 · Cited by 12
Impact of Age at Diagnosis on Cardiotoxicity in High-Grade Osteosarcoma and Ewing Sarcoma Patients
Heemelaar, J. C., Speetjens, F. M., Jaff, A. A. M. A., Evenhuis, R. E., Polomski, E. A. S., Mertens, B. J. A., Jukema, J. W., Gelderblom, H. A. J., van de Sande, M. A. J., & Antoni, M. L. (2023) · JACC CardioOncology · doi:10.1016/j.jaccao.2022.11.016 · Cited by 12
Gürdoğan, M. (2023) · The Anatolian Journal of Cardiology · doi:10.14744/anatoljcardiol.2023.3013 · Cited by 12
Calabria, E., Antonelli, A., Barone, S., Adamo, D., Salviati, M., Cerra, M. G., Bennardo, F., & Giudice, A. (2023) · Dentistry Journal · doi:10.3390/dj11060147 · Cited by 12
Dent, S. F., Botros, J., Rushton, M. K., Aseyev, O., Levine, M. N., Parulekar, W. R., O’Brien, P., Burnell, M. J., Pritchard, K. I., Chen, B. E., et al. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05887-w · Cited by 12
Self-citationBardaro, F., & Stirpe, E. (2022) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552211073823 · Cited by 12
Pizzamiglio, S., Ciniselli, C. M., de Azambuja, E., Agbor‐Tarh, D., Moreno‐Aspitia, A., Suter, T. M., Trama, A., Santis, M. C. D., Cecco, L. D., Iorio, M. V., et al. (2024) · Breast Cancer Research and Treatment · doi:10.1007/s10549-024-07299-6 · Cited by 11
Cancer progression and tumor hypercoagulability: a platelet perspective
Zhang, Y., Zeng, J., Bao, S., Zhang, B., Li, X., Wang, H., Cheng, Y., Zhang, H., Zu, L., Xu, X. N., et al. (2024) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-024-02993-0 · Cited by 12
Amini, A., Zaha, V. G., Hamad, E. A., Woodard, P. K., Rimner, A., Chang, J. Y., Chun, S. G., Donington, J. S., Edelman, M. J., Gubens, M. A., et al. (2024) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.09.1433 · Cited by 11
Zeng, C., Gao, Y., Lan, B., Wang, J., & Ma, F. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.05.009 · Cited by 12
Spadafora, L., Muro, F. M. D., Intonti, C., Massa, L., Monelli, M., Pedretti, R. F. E., Adriano, E. P., Guarini, P., Cantiello, G., Bernardi, M., et al. (2025) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd12060212 · Cited by 12
Trends in the Use of Cardiac Imaging for Women with Newly Diagnosed Breast Cancer
Barac, A., Isaacs, C. J., Shara, N. M., Lynce, F. C., Desale, S. Y., Haynes, K., & Potosky, A. L. (2020) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-020-10023-6 · Cited by 11
Self-citationJafari, L., & Akhter, N. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06096-9 · Cited by 11
Sreenivasan, J., Hooda, U., Ranjan, P., & Jain, D. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01493-4 · Cited by 11
Yu, C., Pathan, F. K., Tan, T. C., & Negishi, K. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.728215 · Cited by 11
Pediatric Cardio-Oncology Medicine: A New Approach in Cardiovascular Care
Martinez, H. R., Beasley, G. S., Goldberg, J. F., Absi, M. A., Ryan, K. A., Guerrier, K., Joshi, V. M., Johnson, J. N., Morin, C. E., Hurley, C., et al. (2021) · Children · doi:10.3390/children8121200 · Cited by 11
Management and treatment of cardiotoxicity due to anticancer drugs: 10 questions and answers
Chianca, M., Fabiani, I., Franco, A. D., Grigoratos, C., Aimo, A., Panichella, G., Giannoni, A., Castiglione, V., Gentile, F., Passino, C., et al. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwac170 · Cited by 11
Self-citationAltena, R., Bajalica‐Lagercrantz, S., & Papakonstantinou, A. (2022) · Cancers · doi:10.3390/cancers14194665 · Cited by 11
Mauro, C., Capone, V., Cocchia, R., Cademartiri, F., Riccardi, F., Arcopinto, M., Alshahid, M., Anwar, K., Carafa, M., Carbone, A., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041612 · Cited by 13
Viamonte, S., Tavares, A. I., Alves, A. J., Joaquim, A. V., Vilela, E., Capela, A., Costa, A. J., Duarte, B., Rato, N. D., Afreixo, V. M. A., et al. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae181 · Cited by 11
Cardiovascular Complications of Novel Anti-Cancer Immunotherapy: Old Problems from New Agents?
Chung, W., Youn, J., & Youn, H. (2020) · Korean Circulation Journal · doi:10.4070/kcj.2020.0158 · Cited by 11
Cardio-oncology: rationale, aims and future directions
Pan, J., Garza, F., & Lyon, A. R. (2021) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0000000000000544 · Cited by 11
Self-citationWhat Does a Cardio-oncology Service Offer to the Oncologist and the Haematologist?
Andrés, M. S., Pan, J., & Lyon, A. R. (2021) · Clinical Oncology · doi:10.1016/j.clon.2021.03.012 · Cited by 11
Self-citationCanale, M. L., Turazza, F. M., Lestuzzi, C., Parrini, I., Camerini, A., Russo, G., Colivicchi, F., Gabrielli, D., Gulizia, M. M., Oliva, S., et al. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.677544 · Cited by 11
Treatment strategies for a rapidly evolving landscape in chronic lymphocytic leukemia management
Eyre, T. A., Hori, S., & Munir, T. (2021) · Hematological Oncology · doi:10.1002/hon.2943 · Cited by 11
Spectrum of National Institutes of Health-Funded Research in Cardio-Oncology
Adhikari, B. B., Shi, S., Dimond, E. P., Shelburne, N., Desvigne-Nickens, P. M., & Minasian, L. M. (2022) · Heart Failure Clinics · doi:10.1016/j.hfc.2022.01.001 · Cited by 11
Henriksen, P. A., Hall, P. S., Oikonomidou, O., Macpherson, I. R., Maclean, M., Lewis, S. C., McVicars, H., Broom, A., Scott, F., McKay, P., et al. (2022) · Circulation Heart Failure · doi:10.1161/circheartfailure.121.009445 · Cited by 11
Hecker-Nolting, S., Langer, T., Blattmann, C., Kager, L., & Bielack, S. S. (2021) · Cancer Management and Research · doi:10.2147/cmar.s287908 · Cited by 10
The role of stress echocardiography in identifying cardiotoxicity: an in-depth exploration
Wang, S., Wang, S., & Wang, S. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1236966 · Cited by 10
Insight of immune checkpoint inhibitor related myocarditis
Pi, J.-K., Chen, X.-T., Zhang, Y., Chen, X.-M., Wang, Y.-C., Xu, J., Zhou, J.-H., Yu, S.-S., & Wu, S. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113559 · Cited by 11
A review of cardioprotective effect of ginsenosides in chemotherapy-induced cardiotoxicity
Zare‐Zardini, H., Hedayati-Goudarzi, M.-T., Alizadeh, A., Sadeghian‐Nodoushan, F., & Soltaninejad, H. (2024) · BioMedical Engineering OnLine · doi:10.1186/s12938-024-01322-z · Cited by 10
Sanglikar, G., & Tengli, A. K. (2025) · Results in Chemistry · doi:10.1016/j.rechem.2025.102210 · Cited by 10
Vacharanukrauh, P., Miller, K. J., Alif, S. M., Grace, F., & Rahman, M. A. (2025) · Breast Cancer Research and Treatment · doi:10.1007/s10549-025-07791-7 · Cited by 10
Role of GLP‐1 Receptor Agonists in Managing Cancer Therapy–Related Cardiac Dysfunction
Vignarajah, A., Kim, S., Albliwi, M., Ahn, H. M., Izda, A., Naffa, F., Vigneswaramoorthy, N. A., Barot, S. V., & Shah, G. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.125.040919 · Cited by 10
de Mello‐Sampayo, F., Fiúza, M., Pinto, F. J., & Fontes, J. (2021) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2020.09.012 · Cited by 10
The year in cardiovascular medicine 2021: cardio-oncology
Herrmann, J., López‐Fernández, T., & Lyon, A. R. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab891 · Cited by 10
Self-citationAsymptomatic Myocarditis with Mild Cardiac Marker Elevation Following Nivolumab-Induced Myositis
Shindo, A., Yamasaki, M., Uchino, K., & Yamasaki, M. (2022) · International Heart Journal · doi:10.1536/ihj.21-653 · Cited by 12
Potential Role of Neutrophil Extracellular Traps in Cardio-Oncology
Cheng, K., Contreras, G. P., & Yeh, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073573 · Cited by 10
Chemotherapy as a possible trigger for the myocardial lipomatosis development
Арманович, А. А., Mkrtchyan, L., Конончук, Н. Б., Kaktursky, L. V., & Agati, L. (2022) · Arterial’naya Gipertenziya (Arterial Hypertension) · doi:10.18705/1607-419x-2021-27-6-706-712 · Cited by 10
Can We Mitigate Coronary Heart Disease Risk in Patients with Cancer?
Manohar, H. D., Potter, A. S., Koutroumpakis, E., Deswal, A. M., & Palaskas, N. L. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01035-5 · Cited by 10
Cardiac Toxicities in Oncology: Elucidating the Dark Box in the Era of Precision Medicine
Samuel, Y., Babu, A., Karagkouni, F., Ismail, A., Choi, S., & Boussios, S. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45100526 · Cited by 10
Micheletti, P. L., da Silva, J. C., Scandolara, T. B., Kern, R., Alves, V. D., Malanowski, J., Victorino, V. J., Herrera, A. C. S. A., Rech, D., Souza, J. A. O., et al. (2021) · Journal of Chemotherapy · doi:10.1080/1120009x.2021.1873632 · Cited by 10
Ballesteros, A. L., Lobo, R. S., Valencia, J. C. V., Arévalo-Leal, O. G., Hernández, D., Aponte, N., & Ramírez, I. P. (2021) · Colombia medica · doi:10.25100/cm.v52i1.4542 · Cited by 10
Cardiotoxicity of adjuvant chemotherapy with trastuzumab: a Japanese claim-based data analysis
Ohtsu, H., Shimomura, A., Miyazaki, S., Yonemoto, N., Ueda, S., Shimizu, C., & Sase, K. (2022) · Open Heart · doi:10.1136/openhrt-2022-002053 · Cited by 10
Diversity of Cardiologic Issues in a Contemporary Cohort of Women With Breast Cancer
Tini, G., Ameri, P., Buzzatti, G., Sarocchi, M., Murialdo, R., Guglielmi, G., Arboscello, E., Ballestrero, A., Mastro, L. D., Spallarossa, P., et al. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.654728 · Cited by 10
Chianca, M., L’Abbate, S., Fabiani, I., Aimo, A., Emdin, M., Passino, C., Fedele, A., Cipolla, C. M., & Cardinale, D. M. (2023) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2023.2197589 · Cited by 10
Self-citationWright, J. L., Amini, A., Bergom, C. R., & Milgrom, S. A. (2023) · Practical Radiation Oncology · doi:10.1016/j.prro.2023.08.008 · Cited by 9
Breast Cancer and Therapy-Related Cardiovascular Toxicity
Hwang, H., Han, S., & Sohn, I. S. (2024) · Journal of Breast Cancer · doi:10.4048/jbc.2024.0085 · Cited by 10
Terluk, A., Stefani, L. D., Boyd, A. C., Vo, K., Byth, K., Hui, R., Richards, D., & Thomas, L. (2024) · ESC Heart Failure · doi:10.1002/ehf2.14884 · Cited by 9
Zheng, S., Chen, R., Zhang, L., Tan, L., Li, L., Long, F., & Wang, T. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116702 · Cited by 11
Travers, S., Alexandre, J., Baldassarre, L. A., Salem, J., & Mirabel, M. (2025) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2024.12.012 · Cited by 10
Cardiotoxicity in Breast Cancer Therapy: Risks, Mechanisms, and Prevention Strategies
Fitrianti, A. E., Wardani, N. O., Astuti, A., Anggadiredja, K., Amalia, L., Putri, R. A., & Zazuli, Z. (2025) · Medical Sciences · doi:10.3390/medsci13030130 · Cited by 11
Liang, L., Luo, C., Dong, S., Jia, Z., Zhao, L., Tang, J., Li, M., Zong, X., Li, S., & Ab‐Ghani, Z. (2025) · Discover Oncology · doi:10.1007/s12672-025-03299-0 · Cited by 10
Targeting pathological ERK1/2 signaling in cancer and beyond
Schanbacher, C., Goebeler, M.-E., Gerull, B., & Lorenz, K. (2025) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2025.08.001 · Cited by 13
Migliari, M., Fazzini, L., Campana, N., Deidda, M., Dessì, M., & Dessalvi, C. C. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1668308 · Cited by 11
Genetic Factors Involved in Cardiomyopathies and in Cancer
Molina, M. S., Peñalver, M. N., Muñoz‐Esparza, C., Esteban-Gil, Á., Mateo, J. J. S., & Gimeno, J. R. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061702 · Cited by 8
Right ventricular function during trastuzumab therapy for breast cancer
Mazzutti, G., Júnior, F. P., Costa, G. O. M., Foppa, M., Biolo, A., & Santos, Â. B. S. (2021) · The International Journal of Cardiovascular Imaging · doi:10.1007/s10554-021-02470-2 · Cited by 9
Outcomes of malignancy in adults with congenital heart disease: a single center experience
Venkatesh, P., Yan, K. L., Bravo‐Jaimes, K., Yang, E. H., & Lluri, G. (2022) · Cardio-Oncology · doi:10.1186/s40959-022-00144-z · Cited by 9
Moustafa, I., Viljoen, M., Perumal-Pillay, V. A., & Oosthuizen, F. (2022) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552221147660 · Cited by 9
Knowles, R., Kemp, E., Miller, M., & Koczwara, B. (2023) · Journal of Cancer Survivorship · doi:10.1007/s11764-023-01331-2 · Cited by 9
Ferreira, V. V., & Ghosh, A. K. (2023) · Clinical Medicine · doi:10.7861/clinmed.2022-0588 · Cited by 9
Reduced cardiovascular reserve capacity in long-term allogeneic stem cell transplant survivors
Dillon, H. T., Foulkes, S., Horne-Okano, Y. A., Kliman, D. S., Dunstan, D. W., Daly, R. M., Fraser, S. F., Avery, S., Kingwell, B. A., Gerche, A. L., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-28320-w · Cited by 9
DeRemer, D. L., Nguyen, N., Guha, A., Ahmad, F. S., Cooper‐DeHoff, R. M., Pepine, C. J., Fradley, M. G., & Gong, Y. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.027981 · Cited by 9
Self-citationAdvances in Screening for Radiation-Associated Cardiotoxicity in Cancer Patients
Schiffer, W. B., Pedersen, L. N., Lui, M., Bergom, C. R., & Mitchell, J. D. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01971-x · Cited by 9
Self-citationBirch, S. C. M., & Otton, J. M. (2024) · Journal of Medical Imaging and Radiation Oncology · doi:10.1111/1754-9485.13724 · Cited by 9
Szmit, S., Grela-Wojewoda, A., Talerczyk, M., Kufel-Grabowska, J., Streb, J., Smok-Kalwat, J., Iżycki, D., Chmielowska, E., Wilk, M., & Sosnowska‐Pasiarska, B. (2020) · Scientific Reports · doi:10.1038/s41598-020-75614-4 · Cited by 9
ONCOR: design of the Dutch cardio-oncology registry
Kamphuis, J. A. M., Linschoten, M., Cramer, M. J., Alsemgeest, F., van Kessel, D. J. W., Urgel, K., Post, M. C., Manintveld, O. C., Hassing, H. C., Liesting, C., et al. (2020) · Netherlands Heart Journal · doi:10.1007/s12471-020-01517-8 · Cited by 9
Emelina, E. I., Gendlin, G. E., & Nikitin, I. G. (2021) · Clinical oncohematology · doi:10.21320/2500-2139-2021-14-2-239-261 · Cited by 9
Gerardi, C., Allocati, E., Minoia, C., Guarini, A., & Banzi, R. (2021) · Cancers · doi:10.3390/cancers13122976 · Cited by 9
Cardio-oncology for the general cardiologist
Tan, L., & Lyon, A. R. (2021) · Heart · doi:10.1136/heartjnl-2020-317871 · Cited by 9
Self-citationBouwer, N. I., Liesting, C., Kofflard, M. J. M., Brugts, J. J., Kock, M. C. J. M., Kitzen, J. J. E. M., Levin, M., & Boersma, E. H. (2021) · Cardiovascular Ultrasound · doi:10.1186/s12947-021-00266-x · Cited by 9
Chemotherapy‐associated cardiomyopathy: Mechanisms of toxicity and cardioprotective strategies
Veeder, J. A., Hothem, L. N., Cipriani, A., Jensen, B. C., & Rodgers, J. E. (2021) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2638 · Cited by 9
Wei, X., Lin, L., Zhang, G., & Zhou, C. (2022) · Diagnostics · doi:10.3390/diagnostics12081846 · Cited by 9
Metadata
- Authors
- Curigliano, G., Lenihan, D., Fradley, M., Ganatra, S., Barac, A., Blaes, A., Herrmann, J., Porter, C., Lyon, A. R., Lancellotti, P., Patel, A., DeCara, J., Mitchell, J., Harrison, E., Moslehi, J., Witteles, R., Calabro, M. G., Orecchia, R., de Azambuja, E., Zamorano, J. L., Krone, R., Iakobishvili, Z., Carver, J., Armenian, S., Ky, B., Cardinale, D., Cipolla, C. M., Dent, S., & Jordan, K.
- Affiliations
- University of Milan (IT)
- Washington University Medical Center (US)
- University of South Florida (US)
- Lahey Hospital and Medical Center (US)
- Georgetown University (US)
- University of Minnesota (US)
- Mayo Clinic (US)
- University of Kansas Medical Center (US)
- Royal Brompton Hospital (GB)
- Centre Hospitalier Universitaire de Liège (BE)
- University of Chicago (US)
- Vanderbilt University (US)
- Stanford Medicine (US)
- European Institute of Oncology (IT)
- Hospital Universitario Ramón y Cajal (ES)
- Washington University in St. Louis (US)
- Tel Aviv University (IL)
- Hospital of the University of Pennsylvania (US)
- City Of Hope National Medical Center (US)
- University of Pennsylvania (US)
- Duke University (US)
- Heidelberg University (DE)
- ORCID
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2020-02
- Volume
- 31
- Issue
- 2
- Pages
- 171-190
- ISSN
- 0923-7534 (ISSN-L)
- PMC
- PMC8019325
- OpenAlex
- W2999536665
- Cited by
- 1,031
- References
- 221
- Citations by year
- 2026: 108 · 2025: 152 · 2024: 168 · 2023: 189 · 2022: 188 · 2021: 143 · 2020: 83
- FWCI
- 93.28
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Annals of Oncology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- ORBi (University of Liège) (submittedVersion, other-oa)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- HF
- Genentech
- Amgen
- Servier
- Pfizer
- Bristol-Myers Squibb
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Chemotherapy-induced cardiotoxicity and mitigation
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac tumors and thrombi
- Health Sciences › Medicine › Infectious Diseases › HIV-related health complications and treatments
- Keywords
- cardio-oncology, cardiotoxicity, cancer therapy, heart failure, cardiovascular screening, cardiovascular monitoring, novel cancer therapies, cardiovascular disease in cancer patients
- MeSH terms
- Antineoplastic Agents, Heart Diseases, Humans, Medical Oncology, Neoplasms, Consensus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
